Ramucirumab (CYRAMZA) / VEGFR2 Cancer Research Results

Ramu, Ramucirumab (CYRAMZA): Click to Expand ⟱
Features:
Ramucirumab (CYRAMZA) is a fully human IgG1 monoclonal antibody that binds VEGFR-2 (KDR/Flk-1) on endothelial cells and blocks VEGF-A/VEGF-C/VEGF-D from activating the receptor, thereby suppressing VEGFR-2 phosphorylation and downstream pro-angiogenic signaling (endothelial proliferation, migration, survival, and vascular permeability). Clinically, it’s used as an anti-angiogenic therapy across multiple solid tumors (labelled indications include advanced/metastatic gastric/GEJ adenocarcinoma, NSCLC in specific combinations/settings, metastatic colorectal cancer in combination therapy, and AFP-high hepatocellular carcinoma after prior therapy).

Pathways/axes ramucirumab functionally down-modulates (via VEGFR-2 blockade)
-VEGF ligand → VEGFR-2 angiogenesis axis (core target): vessel sprouting, endothelial survival, migration, permeability.
-PI3K → AKT (PKB) survival signaling downstream of VEGFR-2 (endothelial cell survival/anti-apoptosis).
-RAS → RAF → MEK → ERK (MAPK) proliferation signaling downstream of VEGFR-2 (endothelial proliferation).
-PLCγ → PKC signaling downstream of VEGFR-2 (linked to permeability and other endothelial responses).
-Src-family kinases / TSAd–Src modules and FAK/integrin–cytoskeleton signaling (migration, adhesion, barrier regulation).
-eNOS → nitric oxide (NO) signaling (vascular tone/permeability; intersects with Src and PLCγ signaling). -Vascular permeability & “vascular normalization” effects that can secondarily modulate tumor hypoxia/HIF programs and immune cell trafficking/antitumor immunity in the microenvironment (context-dependent).
VEGFR2, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2 is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
5283- Ramu,    Ramucirumab
- Review, Var, NA
VEGFR2↓,
5284- Ramu,    https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/
- Review, Var, NA
VEGFR2↓, OS↑, angioG↓, toxicity↝, ChemoSen↑, Dose↝,
5286- Ramu,    Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
- Review, GC, NA
VEGFR2↓, OS↑, toxicity↝,
5287- Ramu,    Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
- in-vivo, GC, NA
VEGFR2↓, OS↑, OS↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 4,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,  

Functional Outcomes ⓘ

OS↑, 4,   toxicity↝, 2,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: VEGFR2, Vascular Endothelial Growth Factor Receptor 2
4 Ramucirumab (CYRAMZA)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:229  Target#:768  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page